Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting

Rhea-AI Summary

Cara Therapeutics (NASDAQ: CARA) announced that biomarker data from the KARE Phase 2 clinical trial of Oral KORSUVA™ (difelikefalin) for treating moderate-to-severe pruritus in atopic dermatitis will be presented at the 2022 AAD Annual Meeting on March 26, 2022. The company will also host a virtual R&D event on March 11, 2022, to discuss Phase 3 programs for pruritus in advanced chronic kidney disease and atopic dermatitis. The KORSUVA injection is the first FDA-approved treatment for chronic kidney disease-related pruritus.

Positive

• Presentation of promising biomarker data from Phase 2 clinical trial.
• Hosting a virtual R&D event to discuss Phase 3 trials, potentially signaling growing therapeutic options.
• First FDA-approved treatment for pruritus in chronic kidney disease patients enhances credibility.

Negative

• None.

Oral presentation will include biomarker data from KARE Phase 2 clinical trial of Oral KORSUVA™ (difelikefalin) for the treatment of moderate-to-severe pruritus in atopic dermatitis patients

Oral KORSUVA (difelikefalin) Phase 3 pruritus programs in non-dialysis dependent advanced chronic kidney disease and atopic dermatitis, respectively, to be discussed during Company’s virtual R&D event on March 11, 2022, at 1 p.m. ET

STAMFORD, Conn., March 08, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced biomarker data from the KARE Phase 2 clinical trial evaluating Oral KORSUVA™ (difelikefalin) for the treatment of moderate-to-severe pruritus in atopic dermatitis patients will be presented in a late-breaking oral presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting, to be held March 25-29, 2022, in Boston, MA.

Details for the late-breaking oral presentation are as follows:

Title: Oral Difelikefalin Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Subjects With Moderate-to-Severe Pruritus
Session: S026 – Late-Breaking Research: Clinical Trials
Date and Time: Saturday, March 26, 2022, 9:40 a.m. ET
Location: Room 210A
Presenter: Paola Facheris, MD, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy

Virtual R&D Event

As previously announced, Cara Therapeutics will be hosting a virtual R&D event at 1:00 p.m. ET on March 11, 2022, which will focus on the initiation of Oral KORSUVA (difelikefalin) Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis, respectively. An interactive Q&A session will follow the presentation. Presenters will include:

• Christopher Posner, President & Chief Executive Officer and Director of Cara Therapeutics
• Joana Goncalves, MD, Chief Medical Officer of Cara Therapeutics
• Brian Kim, MD, MTR, Icahn School of Medicine at Mount Sinai, NY
• Jonathan Silverberg, MD, PhD, MPH, George Washington University School of Medicine and Health Sciences

A live audio webcast of the presentation and accompanying slides will be accessible under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. A replay of the webcast will be archived on the Company’s website following the presentation.  

About Cara Therapeutics

Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and plans to initiate Phase 3 programs in the first quarter of 2022 for the treatment of pruritus in patients with non-dialysis-dependent advanced chronic kidney disease and atopic dermatitis. Phase 2 trials of Oral KORSUVA (difelikefalin) are ongoing in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com

FAQ

What data will be presented by Cara Therapeutics at the AAD Annual Meeting?

Cara Therapeutics will present biomarker data from the KARE Phase 2 clinical trial of Oral KORSUVA for treating moderate-to-severe pruritus in atopic dermatitis.

When is Cara Therapeutics' virtual R&D event scheduled?

The virtual R&D event is scheduled for March 11, 2022, at 1:00 p.m. ET.

What is the significance of KORSUVA in chronic kidney disease?

KORSUVA is the first FDA-approved treatment specifically for moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients.

What are the future plans for Oral KORSUVA?

Cara Therapeutics plans to initiate Phase 3 programs for Oral KORSUVA to treat pruritus in non-dialysis-dependent advanced chronic kidney disease and atopic dermatitis in 2022.